The stock of Aralez Pharmaceuticals Inc (TSE:ARZ) is a huge mover today! About 44,729 shares traded hands or 150.27% up from the average. Aralez Pharmaceuticals Inc (TSE:ARZ) has risen 42.53% since April 12, 2016 and is uptrending. It has outperformed by 37.84% the S&P500.
The move comes after 9 months positive chart setup for the $456.02 million company. It was reported on Nov, 16 by Barchart.com. We have $12.08 PT which if reached, will make TSE:ARZ worth $314.65 million more.
More notable recent Aralez Pharmaceuticals Inc (TSE:ARZ) news were published by: Seekingalpha.com which released: “Pleasant Surprises Ahead For Aralez Pharmaceuticals’ Shareholders” on November 14, 2016, also Seekingalpha.com with their article: “CEO Adrian Adams Is Prepping Aralez For A Sale” published on November 15, 2016, Fool.com published: “Why Aralez Pharmaceuticals Inc Jumped Higher Today” on August 01, 2016. More interesting news about Aralez Pharmaceuticals Inc (TSE:ARZ) were released by: Fool.com and their article: “Why Aralez Pharmaceuticals Inc. Approved a Higher Price Today” published on September 15, 2016 as well as Marketwatch.com‘s news article titled: “/quotes/zigman/3870025/realtime” with publication date: February 12, 2016.
Aralez Pharmaceuticals Inc. is a Canada specialty pharmaceutical company. The company has a market cap of $456.02 million. The Firm focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. It currently has negative earnings. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.